文献速递淋巴瘤

R-CVP与R-CHOP一线诱导免疫化疗联合利妥昔单抗维持治疗惰性淋巴瘤:PLRG4随机III期研究最终结果

First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
PubMed 文献 · Br J Haematol · 2019-12-02

中位随访约5年以上,两组5年EFS、PFS和OS均无显著差异,但R-CHOP组III/IV级不良事件、中性粒细胞减少和感染显著更多。R-CVP因毒性更低可作为合理诱导选择。

要点

  • R-CVP与R-CHOP诱导后利妥昔单抗维持的5年EFS、PFS和OS无显著差异。
  • R-CHOP组III/IV级不良事件、中性粒细胞减少和感染发生率显著高于R-CVP组。
  • R-CVP因毒性较低可作为惰性淋巴瘤诱导治疗的合理选择。

核心结论

  • 在需要全身治疗的惰性淋巴瘤患者中,R-CVP与R-CHOP诱导后联合利妥昔单抗维持的长期生存结局相似。
  • R-CVP方案毒性较低,可作为合理的诱导治疗选择,将多柔比星或苯达莫司汀等药物留作二线治疗。

研究设计与样本

  • 多中心、III期随机研究,由波兰淋巴瘤研究组开展。
  • 诱导方案为8个周期或至完全缓解,达到CR/PR者接受利妥昔单抗维持治疗375 mg/m2,每2个月一次,共12个周期。
  • 主要终点为无事件生存期(EFS)。

主要发现

  • 中位随访分别为67、66和70个月,R-CHOP组与R-CVP组的5年EFS为61% vs. 56%(无显著差异),PFS为71% vs. 69%(无显著差异),OS为84% vs. 89%。
  • 第二肿瘤在R-CHOP组和R-CVP组分别为3例和7例。

临床怎么用

  • 对于需要全身治疗的惰性淋巴瘤患者,R-CVP诱导后利妥昔单抗维持可作为毒性较低的合理一线选择。
  • R-CHOP方案虽然疗效相似,但III/IV级不良事件、中性粒细胞减少和感染风险更高,需权衡毒性。
  • 将多柔比星或苯达莫司汀等药物保留用于二线治疗可能是合理的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

R-CVP (cyclophosphamide, vincristine, prednisone) and R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone + rituximab) are immunochemotherapy regimens frequently used for remission induction of indolent non-Hodgkin lymphomas (iNHLs). Rituximab maintenance (RM) significantly improves progression-free survival (PFS) in patients with complete/partial remission (CR/PR). Here we report the final results of a randomized study comparing R-CVP to R-CHOP both followed by RM. Untreated patients in need of systemic therapy with symptomatic and progressive iNHLs including follicular (FL) and marginal zone lymphoma (MZL), mucosa-associated lymphoid tissue (MALT), small lymphocytic (SLL), and lymphoplasmacytic (LPL) lymphoma were eligible. Patients were randomized to receive R-CVP or R-CHOP for eight cycles or until complete response (CR). All patients with CR/PR (partial response) received RM 375 mg/m2 q 2 months for 12 cycles. Primary endpoint was event-free survival (EFS). Two-hundred and fifty patients [FL 42%, MZL/MALT 38%, LPL/ Waldenström Macroglobulinaemia (WM) 11%, SLL 9%] were enrolled and randomized (R-CHOP: 127, R-CVP: 123). Median age was 56 years (21-85), 44% were male, 90% were in stage III-IV, 43% of FL patients had a Follicular Lymphoma International Prognostic Index (FLIPI) score ≥3, and 33·4% of all patients had an IPI score ≥3. At the end of induction treatment, the CR/PR rate was 43·6/50·9% and 36·3/60·8% in the R-CHOP and R-CVP groups (P = 0·218) respectively. After a median follow-up of 67, 66, and 70 months, five-year EFS was 61% vs. 56% (not significant), progression-free survival (PFS) was 71% vs. 69% (not significant) and overall survival (OS) was 84% vs. 89% in the R-CHOP vs. the R-CVP arm respectively. Grade III/IV adverse events (65 vs. 22) occurred in 40 (33·1%) and 18 (15·3%) patients, P = 0·001; neutropenia in 16 (11·6%) and 4 (3·4%) patients, P = 0·017; infection in 14 (10·7%) and 3 (2·5%) patients,; P = 0·011; and a second neoplasm in three versus seven patients., in the R-CHOP and the R-CVP groups respectively. This multicentre randomized study with >five-year follow-up shows similar outcome in patients with indolent lymphoma in need of systemic therapy treated with R-CVP or R-CHOP immunochemotherapy and rituximab maintenance in both arms. The minor toxicity of the R-CVP regimen makes it a reasonable choice for induction treatment, leaving other active agents like doxorubicin or bendamustin for second-line therapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Walewski J, Paszkiewicz-Kozik E, Michalski W, et al. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Br J Haematol. 2019. PMID: 31792945. doi:10.1111/bjh.16264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。